NYSE:AIM AIM ImmunoTech Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.78 +0.00 (+0.13%) (As of 07/1/2022 03:16 PM ET) Add Compare Share Today's Range$0.78▼$0.7950-Day Range$0.78▼$1.0852-Week Range$0.55▼$2.20Volume500 shsAverage Volume115,062 shsMarket Capitalization$37.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media AIM ImmunoTech MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.35 out of 5 starsMedical Sector1370th out of 1,428 stocksBiological Products, Except Diagnostic Industry209th out of 218 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for AIM ImmunoTech. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for AIM. Previous Next 0.0 Dividend Strength Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AIM. Previous Next 1.1 News and Social Media Coverage News SentimentAIM ImmunoTech has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AIM ImmunoTech this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by InstitutionsOnly 16.05% of the stock of AIM ImmunoTech is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAIM ImmunoTech has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address About AIM ImmunoTech (NYSE:AIM) StockAIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock News HeadlinesJuly 4, 2022 | americanbankingnews.comCuris (NASDAQ:CRIS) & AIM ImmunoTech (NYSE:AIM) Financial ReviewJune 21, 2022 | ca.proactiveinvestors.comAIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in New JerseyJune 21, 2022 | finance.yahoo.comAIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and TestingJune 13, 2022 | ca.proactiveinvestors.comAIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen and dsRNA products aimed at COVID-19June 13, 2022 | finance.yahoo.comAIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or PreventionJune 10, 2022 | americanbankingnews.comCidara Therapeutics (NASDAQ:CDTX) and AIM ImmunoTech (NYSE:AIM) Head to Head ComparisonMay 18, 2022 | proactiveinvestors.com.auAIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVIDMay 16, 2022 | finance.yahoo.comAIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 21, 2022 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade TherapiesApril 12, 2022 | proactiveinvestors.comAIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen studyApril 12, 2022 | finance.yahoo.comAIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic CancerApril 11, 2022 | tmcnet.comAIM ImmunoTech Announces Positive Data from Phase 2aApril 11, 2022 | nasdaq.comAIM ImmunoTech Up 8% As Its Ampligen To Treat Breast Cancer Meets Primary GoalApril 11, 2022 | finance.yahoo.comAIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer SettingApril 1, 2022 | proactiveinvestors.comAIM ImmunoTech reports ‘strong’ balance sheet to fund operations and clinical development programs through 2023March 29, 2022 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World CongressMarch 29, 2022 | finance.yahoo.comInvestors in Ai-Media Technologies (ASX:AIM) have unfortunately lost 30% over the last yearMarch 28, 2022 | proactiveinvestors.comAIM ImmunoTech says data from Ampligen study on pancreatic cancer accepted for presentation at upcoming IHPBA World CongressMarch 28, 2022 | finance.yahoo.comAIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World CongressMarch 24, 2022 | finance.yahoo.comAIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual MeetingMarch 18, 2022 | seekingalpha.comAIM Immunotech stock soars 25% as FDA lifts hold, paving way for pancreatic cancer studyMarch 16, 2022 | msn.comFDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic CancerMarch 16, 2022 | proactiveinvestors.comAIM ImmunoTech wins IND clearance from FDA to proceed with Phase 2 study of Ampligen for treating locally advanced pancreatic cancerMarch 16, 2022 | finance.yahoo.comAIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerMarch 15, 2022 | proactiveinvestors.comAIM ImmunoTech hails positive data from Ampligen study on advanced, metastatic pancreatic cancerSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/05/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,130,000.00 Net Margins-13,933.81% Pretax Margin-13,933.81% Return on Equity-32.98% Return on Assets-32.06% Debt Debt-to-Equity RatioN/A Current Ratio65.77 Quick Ratio65.77 Sales & Book Value Annual Sales$140,000.00 Price / Sales267.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book0.64Miscellaneous Outstanding Shares48,050,000Free Float48,039,000Market Cap$37.48 million OptionableNot Optionable Beta-0.47 AIM ImmunoTech Frequently Asked Questions How has AIM ImmunoTech's stock performed in 2022? AIM ImmunoTech's stock was trading at $0.92 at the beginning of the year. Since then, AIM stock has decreased by 15.2% and is now trading at $0.78. View the best growth stocks for 2022 here. When is AIM ImmunoTech's next earnings date? AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for AIM ImmunoTech. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 32.98% and a negative net margin of 13,933.81%. View AIM ImmunoTech's earnings history. Who are AIM ImmunoTech's key executives? AIM ImmunoTech's management team includes the following people: Mr. Thomas K. Equels Esq., J.D., M.S., Exec. Vice Chairman, CEO & Pres (Age 69, Pay $1.29M)Mr. Peter W. Rodino III, Esq., J.D., COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 71, Pay $585.45k)Mr. Robert Dickey IV, M.B.A., Chief Financial Officer (Age 66)Dr. David R. Strayer M.D., Chief Scientific Officer & Medical Director (Age 76)Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations CoordinatorDr. Carol A. Smith, Chief Manufacturing Officer & Deputy Chief Scientific Officer (Age 71)Jodie Pelz, ControllerDr. Ralph Christopher Cavalli Ph.D., VP of QC & Manufacturing (Age 64) Who are some of AIM ImmunoTech's key competitors? Some companies that are related to AIM ImmunoTech include Fennec Pharmaceuticals (FENC), Taysha Gene Therapies (TSHA), Finch Therapeutics Group (FNCH), Genenta Science (GNTA), Armata Pharmaceuticals (ARMP), Passage Bio (PASG), Big Cypress Acquisition (BCYP), Cellectis (CLLS), Athira Pharma (ATHA), Oyster Point Pharma (OYST), Adverum Biotechnologies (ADVM), Axcella Health (AXLA), TCR2 Therapeutics (TCRR), Surrozen (SRZN) and BioAtla (BCAB). View all of AIM's competitors. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). What is AIM ImmunoTech's stock symbol? AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM." How do I buy shares of AIM ImmunoTech? Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AIM ImmunoTech's stock price today? One share of AIM stock can currently be purchased for approximately $0.78. How much money does AIM ImmunoTech make? AIM ImmunoTech (NYSE:AIM) has a market capitalization of $37.48 million and generates $140,000.00 in revenue each year. The company earns $-19,130,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How many employees does AIM ImmunoTech have? AIM ImmunoTech employs 21 workers across the globe. How can I contact AIM ImmunoTech? AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for AIM ImmunoTech is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739. This page (NYSE:AIM) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
